Published in:
Open Access
01-12-2012 | Research article
Wld
S
but not Nmnat1 protects dopaminergic neurites from MPP+neurotoxicity
Authors:
Jo Ann V Antenor-Dorsey, Karen L O'Malley
Published in:
Molecular Neurodegeneration
|
Issue 1/2012
Login to get access
Abstract
Background
The Wld
S
mouse mutant ("Wallerian degeneration-slow") delays axonal degeneration in a variety of disorders including in vivo models of Parkinson's disease. The mechanisms underlying Wld
S
-mediated axonal protection are unclear, although many studies have attributed Wld
S
neuroprotection to the NAD+-synthesizing Nmnat1 portion of the fusion protein. Here, we used dissociated dopaminergic cultures to test the hypothesis that catalytically active Nmnat1 protects dopaminergic neurons from toxin-mediated axonal injury.
Results
Using mutant mice and lentiviral transduction of dopaminergic neurons, the present findings demonstrate that Wld
S
but not Nmnat1, Nmnat3, or cytoplasmically-targeted Nmnat1 protects dopamine axons from the parkinsonian mimetic N-methyl-4-phenylpyridinium (MPP+). Moreover, NAD+ synthesis is not required since enzymatically-inactive Wld
S
still protects. In addition, NAD+ by itself is axonally protective and together with Wld
S
is additive in the MPP+ model.
Conclusions
Our data suggest that NAD+ and Wld
S
act through separate and possibly parallel mechanisms to protect dopamine axons. As MPP+ is thought to impair mitochondrial function, these results suggest that Wld
S
might be involved in preserving mitochondrial health or maintaining cellular metabolism.